Lina L Reeves Kerner Net Worth

The estimated Net Worth of Lina L Reeves Kerner is at least $26.5 millier dollars as of 19 November 2007. Lina Kerner owns over 1,000 units of Basis Global Technologies Inc stock worth over $26,534 and over the last 21 years Lina sold BASI stock worth over $0.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Lina Kerner BASI stock SEC Form 4 insiders trading

Lina has made over 1 trades of the Basis Global Technologies Inc stock since 2007, according to the Form 4 filled with the SEC. Most recently Lina exercised 1,000 units of BASI stock worth $8,000 on 19 November 2007.

The largest trade Lina's ever made was exercising 1,000 units of Basis Global Technologies Inc stock on 19 November 2007 worth over $8,000. On average, Lina trades about 250 units every 0 days since 2004. As of 19 November 2007 Lina still owns at least 1,614 units of Basis Global Technologies Inc stock.

You can see the complete history of Lina Kerner stock trades at the bottom of the page.

What's Lina Kerner's mailing address?

Lina's mailing address filed with the SEC is 5731 STATE ROAD, 25 SOUTH, WEST POINT, IN, 47992.

Insiders trading at Basis Global Technologies Inc

Over the last 21 years, insiders at Basis Global Technologies Inc have traded over $266,443 worth of Basis Global Technologies Inc stock and bought 540,162 units worth $1,698,287 . The most active insiders traders include Jacqueline M Lemke, Robert Jr. Leasure et William D Pitchford. On average, Basis Global Technologies Inc executives and independent directors trade stock every 65 days with the average trade being worth of $128,544. The most recent stock trade was executed by Beth Taylor on 5 March 2021, trading 5,000 units of BASI stock currently worth $88,500.

What does Basis Global Technologies Inc do?

Complete history of Lina Kerner stock trades at Basis Global Technologies Inc

Basis Global Technologies Inc executives and stock owners

Basis Global Technologies Inc executives and other stock owners filed with the SEC include:

• Wendy Perrow,
  Independent Director
• R. Matthew Neff,
  Independent Director
• Richard Johnson,
  Independent Director
• Joseph Flynn,
  Chief Commercial Officer
• John Sagartz,
  Chief Strategy Officer, Director
• Connie Dougherty,
  Vice President - Business Development
• I.M. Grossi,
  Vice President - Toxicology
• Philip Downing,
  Vice President - Preclinical Services
• Andrew Alexander,
  Vice President - Pharmacology and Toxicology Operations
• Michael Baim,
  Vice President - Bioanalytical Operations
• Beth Taylor,
  Chief Financial Officer, Vice President - Finance
• Robert Leasure,
  President, Chief Executive Officer, Director
• Gregory Davis,
  Interim Chairman of the Board
• Jill Blumhoff,
  VP, Finance & CFO
• John P Devine,
  VP--Toxicology
• James Sevall Bourdage,
  VP, Bioanalytical Services
• Jacqueline M Lemke,
  CFO & Vice President--Finance
• Jeffrey Potrzebowski,
  VP, Finance & CFO
• John Gregory Beattie,
  Chief Operating Officer
• Peterkissinger Candice B Ki...,
  
• Daniel Thomas Oakley,
  Chief Operating Officer
• Kimberly L Sagartz,
  10% owner
• Chrysalis, Llc Sw,
  10% owner
• Lori Payne,
  VP Bioanalytical Services
• Larry Steven Boulet,
  Director
• David W Crabb,
  Director
• John B. Landis,
  Director
• David L Omachinski,
  Director
• Anthony S Chilton,
  COO, Scientific Studies
• A. Charlene Sullivan,
  Director
• Alberto F Jr Hidalgo,
  VP, Bus. Development & Mrkting
• Leslie B Daniels,
  Director
• Kathleen Hodges,
  Vice President of Quality
• Lina L Reeves Kerner,
  V.P. - Human Resources
• Richard M Shepperd,
  President & Chief Exec. Off.
• Ronald E Shoup,
  Chief Operating Officer
• Craig S Bruntlett,
  Sr. V.P. International Sales
• Jon Brewer,
  VP Sales/Marketing
• William E Baitinger,
  Director
• Candice B Kissinger,
  Vice President
• Margaret B Mcclure,
  Dir, Pharmaceutical Lab. Div.
• Michael R Cox,
  V.P. Finance, CFO
• Emilio Cordova,
  V.P. of Business Development
• Edward Chait,
  Executive Vice President
• Gerry Henningsen,
  Director BAS Evansville
• Donnie A Evans,
  Vice President Engineering
• Garyl W Doster,
  Director
• Michael P Silvon,
  Vice President
• Michael S Noone,
  Dir. of Clinical Affairs, Balt
• William Sawyers,
  Laboratory Director
• William D Pitchford,
  Chief HR Officer